

Jeffrey I Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7294871/publications.pdf>

Version: 2024-02-01

70
papers

7,829
citations

94269

37
h-index

88477

70
g-index

73
all docs

73
docs citations

73
times ranked

14444
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	6.0	1,983
2	Herpes Zoster. <i>New England Journal of Medicine</i> , 2013, 369, 255-263.	13.9	541
3	Varicella zoster virus infection. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15016.	18.1	435
4	VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. <i>Science</i> , 2019, 366, 1531-1536.	6.0	344
5	Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2020, 222, 206-213.	1.9	314
6	Epstein-Barr Virus: An Important Vaccine Target for Cancer Prevention. <i>Science Translational Medicine</i> , 2011, 3, 107fs7.	5.8	311
7	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015, 162, 1090-1100.	13.5	278
8	Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. <i>Journal of Experimental Medicine</i> , 2009, 206, 1423-1434.	4.2	269
9	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	269
10	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. <i>Blood</i> , 2011, 117, 5835-5849.	0.6	241
11	Recommendations for Prevention of and Therapy for Exposure to B Virus (Cercopithecine) Tj ETQq1 1 0.784314 rgBT/Overlock, 10 Tf 50	2.9	171
12	Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. <i>Cell</i> , 2021, 184, 1836-1857.e22.	13.5	167
13	Chronic Active Epsteinâ€“Barr Virus Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1867.	2.2	132
14	Epsteinâ€“barr virus vaccines. <i>Clinical and Translational Immunology</i> , 2015, 4, e32.	1.7	128
15	Current understanding of the role of Epsteinâ€“Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. <i>Leukemia and Lymphoma</i> , 2008, 49, 27-34.	0.6	124
16	SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. <i>Science Advances</i> , 2021, 7, .	4.7	117
17	Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. <i>Blood</i> , 2021, 137, 185-189.	0.6	110
18	Primary Immunodeficiencies Associated with EBV Disease. <i>Current Topics in Microbiology and Immunology</i> , 2015, 390, 241-265.	0.7	109

#	ARTICLE	IF	CITATIONS
19	Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. <i>Immunity</i> , 2019, 50, 1305-1316.e6.	6.6	107
20	Vaccine Development for Epstein-Barr Virus. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1045, 477-493.	0.8	92
21	The role of PI3K/Akt in human herpesvirus infection: From the bench to the bedside. <i>Virology</i> , 2015, 479-480, 568-577.	1.1	80
22	Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay. <i>Virology</i> , 2009, 391, 249-256.	1.1	79
23	The need and challenges for development of an Epstein-Barr virus vaccine. <i>Vaccine</i> , 2013, 31, B194-B196.	1.7	77
24	Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. <i>Journal of Clinical Investigation</i> , 2019, 130, 507-522.	3.9	74
25	The murine gammaherpesvirus-68 M11 protein inhibits Fas- and TNF- induced apoptosis. <i>Journal of General Virology</i> , 1999, 80, 2737-2740.	1.3	72
26	In vitro system using human neurons demonstrates that varicella-zoster vaccine virus is impaired for reactivation, but not latency. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2403-12.	3.3	64
27	The Varicella-Zoster Virus Open Reading Frame 63 Latency-Associated Protein Is Critical for Establishment of Latency. <i>Journal of Virology</i> , 2004, 78, 11833-11840.	1.5	58
28	Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers. <i>Clinical Infectious Diseases</i> , 2016, 63, 41-47.	2.9	56
29	THY-1 Cell Surface Antigen (CD90) Has an Important Role in the Initial Stage of Human Cytomegalovirus Infection. <i>PLoS Pathogens</i> , 2015, 11, e1004999.	2.1	51
30	Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Promotes EBV Reactivation through Activation of the p38 Mitogen-Activated Protein Kinase. <i>Journal of Virology</i> , 2016, 90, 1129-1138.	1.5	50
31	Cell Surface THY-1 Contributes to Human Cytomegalovirus Entry via a Macropinocytosis-Like Process. <i>Journal of Virology</i> , 2016, 90, 9766-9781.	1.5	47
32	Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites. <i>Blood</i> , 2019, 133, 2753-2764.	0.6	46
33	Varicella-Zoster Virus ORF4 Latency-Associated Protein Is Important for Establishment of Latency. <i>Journal of Virology</i> , 2005, 79, 6969-6975.	1.5	45
34	Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after Challenge. <i>PLoS Pathogens</i> , 2011, 7, e1002308.	2.1	45
35	Strategies for Herpes Zoster Vaccination of Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2008, 197, S237-S241.	1.9	44
36	A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs. <i>Vaccine</i> , 2016, 34, 101-109.	1.7	42

#	ARTICLE	IF	CITATIONS
37	Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting. <i>Leukemia and Lymphoma</i> , 2020, 61, 808-819.	0.6	42
38	Structural insights into hepatitis C virus receptor binding and entry. <i>Nature</i> , 2021, 598, 521-525.	13.7	38
39	Role of the JNK Pathway in Varicella-Zoster Virus Lytic Infection and Reactivation. <i>Journal of Virology</i> , 2017, 91, .	1.5	36
40	Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis. <i>Journal of Biological Chemistry</i> , 2009, 284, 17102-17109.	1.6	34
41	Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after Primary Infection with EBV. <i>Vaccine Journal</i> , 2016, 23, 363-369.	3.2	34
42	A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. <i>Science Translational Medicine</i> , 2022, 14, eabf3685.	5.8	34
43	High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3451-3457.	3.2	33
44	Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. <i>Seminars in Hematology</i> , 2003, 40, 116-123.	1.8	31
45	Human herpesvirus 6A, 6B, and 7 in vitreous fluid samples. <i>Journal of Medical Virology</i> , 2010, 82, 996-999.	2.5	28
46	Epstein-Barr Virus (EBV) Tegument Protein BGLF2 Suppresses Type I Interferon Signaling To Promote EBV Reactivation. <i>Journal of Virology</i> , 2020, 94, .	1.5	28
47	Kinetics of Serum Cytokines after Primary or Repeat Vaccination with the Smallpox Vaccine. <i>Journal of Infectious Diseases</i> , 2010, 201, 1183-1191.	1.9	25
48	A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2. <i>Journal of Virology</i> , 2016, 90, 562-574.	1.5	21
49	Herpesviruses in the Activated Phosphatidylinositol-3-Kinase- $\hat{\gamma}$ Syndrome. <i>Frontiers in Immunology</i> , 2018, 9, 237.	2.2	21
50	Detection of vaccinia virus DNA, but not infectious virus, in the blood of smallpox vaccine recipients. <i>Vaccine</i> , 2007, 25, 4571-4574.	1.7	20
51	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017, 91, .	1.5	19
52	Human Embryonic Stem Cell-Derived Neurons Are Highly Permissive for Varicella-Zoster Virus Lytic Infection. <i>Journal of Virology</i> , 2018, 92, .	1.5	19
53	Licking latency with licorice. <i>Journal of Clinical Investigation</i> , 2005, 115, 591-593.	3.9	18
54	Varicella-zoster vaccine virus: Evolution in action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7-8.	3.3	17

#	ARTICLE	IF	CITATIONS
55	GATA2 Deficiency and Epstein-Barr Virus Disease. <i>Frontiers in Immunology</i> , 2017, 8, 1869.	2.2	16
56	Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. <i>Journal of Infectious Diseases</i> , 2012, 205, 794-797.	1.9	15
57	Epstein-Barr Virus and the Human Leukocyte Antigen Complex. <i>Current Clinical Microbiology Reports</i> , 2019, 6, 175-181.	1.8	15
58	Detection of Antibodies to Varicella-Zoster Virus in Recipients of the Varicella Vaccine by Using a Luciferase Immunoprecipitation System Assay. <i>Vaccine Journal</i> , 2014, 21, 1288-1291.	3.2	14
59	A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease. <i>Journal of Clinical Immunology</i> , 2022, 42, 108-118.	2.0	14
60	SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793197.	2.2	14
61	Chronic Uveitis in Guinea Pigs Infected with Varicella-Zoster Virus Expressing <i>Escherichia coli</i> β -Galactosidase. <i>Journal of Infectious Diseases</i> , 1998, 177, 293-300.	1.9	12
62	Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune Complexes. <i>Scientific Reports</i> , 2017, 7, 3818.	1.6	10
63	Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model. <i>Vaccine</i> , 2019, 37, 333-342.	1.7	10
64	Activation of H2AX and ATM in varicella-zoster virus (VZV)-infected cells is associated with expression of specific VZV genes. <i>Virology</i> , 2014, 452-453, 52-58.	1.1	9
65	Epstein-Barr virus (EBV) hyperimmune globulin isolated from donors with high gp350 antibody titers protect humanized mice from challenge with EBV. <i>Virology</i> , 2021, 561, 80-86.	1.1	7
66	SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response. <i>Journal of Nephrology</i> , 2022, , 1.	0.9	7
67	Nectin-1 Is an Entry Mediator for Varicella-Zoster Virus Infection of Human Neurons. <i>Journal of Virology</i> , 2021, 95, e0122721.	1.5	6
68	Recurrent scarring papulovesicular lesions on sun-exposed skin in a 22-year-old man. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 637-642.	0.6	5
69	A seroprevalence study of primate workers for asymptomatic rhesus cytomegalovirus infection. <i>Journal of Clinical Virology</i> , 2014, 60, 411-413.	1.6	1
70	Somatic Fas Mutations Account for Nearly One Third of Autoimmune Lymphoproliferative Syndrome (ALPS) Cases with Previously Unknown Genetic Mutations.. <i>Blood</i> , 2009, 114, 710-710.	0.6	0